Lung Cancer (NSCLC)Phase 1NCT07436858
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
A Phase 1 study testing PET imaging with ⁸⁹Zr-trastuzumab and Blood sampling for pharmacokinetics in people with Lung Cancer (NSCLC) and HER2 Expression, run by The Netherlands Cancer Institute at 1 site in Netherlands.
Trial summary
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
- What is being tested?
- PET imaging with ⁸⁹Zr-trastuzumab and Blood sampling for pharmacokinetics
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteNetherlands
- Study dates
- 2 Oct 2026to 2 Aug 2030
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed written informed consent
- Age≥ 18 years, willing and able to comply with the protocol as judged by the investigator
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 at screening.
- Patients with histologically or cytologically confirmed diagnosis of advanced stage:
- HER2 overexpression, defined as an immunohistochemistry score (IHC) of 2+ or 3+ in at least 10% of tumour cells without an activating HER2 mutation
- HER2 activating (insertion) mutation diagnosed through RNA sequencing (RNAseq)
Show all 28Show fewer
- Disease progression after at least one line of platinum-based chemotherapy ± immunotherapy and starting (new) systemic treatment.
- Be willing to provide a recent tumor tissue specimen after the last line of therapy. Samples must be of sufficient quantity and of adequate tumor tissue content.
- Able to undergo PET imaging procedures.
- Measurable disease according to RECIST 1.1.
- At least two measurable lesions with a long axis diameter ≥2 cm.
- Adequate organ and bone marrow function within 21 days prior to tracer injection, defines as:
- Laboratory Test Laboratory Value Platelet count ≥100 000/mm3 or ≥100 × 109/L (platelet transfusions are not allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility) Hemoglobin ≥9.0 g/dL or 5.6 mmol/L (transfusion and/or growth factor support is allowed) Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 × 109/L Aspartate aminotransferase /alanine aminotransferase ≤3 × ULN (if liver metastases are present, ≤5 ×ULN) Total bilirubin ≤1.5 × ULN if no liver metastases (<3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases Creatinine Creatinine clearance (CrCl) ≥30 mL/min as calculated using the Cockcroft-Gault equation.
- International normalised ratio (INR)/Prothrombin time and activated partial thromboplastin time (aPTT) ≤1.5 × (ULN), except for subjects on coumarinderivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator
- Women aged <50 years will be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site.
- Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago.
- Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of childbearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
- Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 3. from the time of screening and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable.
- Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration
- Highly Effective Methods of Contraception (<1% failure rate) include:
- Total heterosexual abstinence (evaluate in relation to the duration of the clinical study and the preferred and usual lifestyle choice of the participant)
- Vasectomised sexual partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomised partner has received medical assessment of the surgical success)
- Bilateral tubal occlusion
- Intrauterine device (provided coils are copper banded)
- Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation i. Oral ii. Intravaginal iii. transdermal
- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral/injectable/implantable)
- Intrauterine hormone-releasing system (IUS)
- All methods of contraception must be used in combination with the use of a condom by their male sexual partners for intercourse.
Who cannot join
- Contraindications for systemic treatment (as will be assigned by the treating physician)
- Pregnant or lactating women
- Prior allergic reaction to immunoglobulins or immunoglobulin allergy
- Inability to comply with study procedures
- Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the study results
- Prior treatment with HER2-targeted therapies (except pan HER TKIs).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Amsterdam, North Holland, 1066CX
Joop de Langen, Dr, +31205129111, j.d.langen@nki.nl
Marianne Mahn, MSc, 31205129111, m.mahn@nki.nl
About this study
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC). The aim is to determine whether differences in tracer uptake can be detected between these groups, as translational studies indicate that HER2-mutated tumors may internalize trastuzumab-based agents more efficiently than tumors that solely overexpressed HER2.
- Conditions
- Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
- Being tested
- PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PET imaging with ⁸⁹Zr-trastuzumabDiagnostic test
Participants will receive one injection of ⁸⁹Zr-trastuzumab and undergo a PET/CT scan four days later.
Blood sampling for pharmacokineticsDiagnostic test
To assess the pharmacokinetics of ⁸⁹Zr-trastuzumab, the investigators collect blood samples at multiple time points following tracer administration. Samples are drawn at 10 minutes, 30 minutes, 1 hour, and 2 hours post-injection, and again on day 4 and day 7 post-injection.
| Study group | Role | What they receive |
|---|---|---|
| HER2-mutated NSCLC cohort and HER2-overexpressing NSCLC cohort | Experimental | Patients with advanced NSCLC carrying an activating HER2 mutation (N=10) Patients with advanced NSCLC whose tumors overexpress HER2, but do not have an activating HER2 mutation (N=10). Receives: Diagnostic Test: PET imaging with ⁸⁹Zr-trastuzumab; Diagnostic Test: Blood sampling for pharmacokinetics |
What is being measured
The primary outcome is the main question the study is designed to answer.
Standard uptake values (SUVs) in tumor lesions
measurable tumor lesions and enlarged lymph nodes (>20 mm)
Measured: During PET imaging with ⁸⁹Zr-trastuzumab
Secondary outcomes (4)
Tumor-to-background ratio (TBR)
Measured: During PET imaging with ⁸⁹Zr-trastuzumab
Tumor-to-plasma ratio (TPR)
Measured: During PET imaging with ⁸⁹Zr-trastuzumab
SUVs in tumor lesions
Measured: During PET imaging with ⁸⁹Zr-trastuzumab
Total expression volume (TEV)
The sum of lesion volumes with uptake above the bloodpool
Measured: During PET imaging with ⁸⁹Zr-trastuzumab
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start2 Oct 2026
- Primary completion2 Aug 2030 (estimated)
- Study completion2 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (NSCLC)Studies of the same condition, open and under way.
- More trials run by The Netherlands Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective explorative imaging
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Netherlands Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07436858
- Sponsor's protocol ID
- N26WBH
- Other IDs
- 2026-525568-17-00
- Status last verified
- Oct 2026
- First submitted
- 17 Feb 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT07436858
- Acronym / sponsor ID
- N26WBH
- Conditions
- Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- The Netherlands Cancer InstituteUniversity, hospital or other
- Study start
- 2 Oct 2026 (actual)
- Primary completion
- 2 Aug 2030 (estimated)
- Study completion
- 2 Aug 2030 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC). The aim is to determine whether differences in tracer uptake can be detected between these groups, as translational studies indicate that HER2-mutated tumors may internalize trastuzumab-based agents more efficiently than tumors that solely overexpressed HER2.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective explorative imaging
| Arm | Type | Receives |
|---|---|---|
| HER2-mutated NSCLC cohort and HER2-overexpressing NSCLC cohort | Experimental | Diagnostic Test: PET imaging with ⁸⁹Zr-trastuzumab, Diagnostic Test: Blood sampling for pharmacokineticsPatients with advanced NSCLC carrying an activating HER2 mutation (N=10) Patients with advanced NSCLC whose tumors overexpress HER2, but do not have an activating HER2 mutation (N=10). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (28 listed)
- Signed written informed consent
- Age≥ 18 years, willing and able to comply with the protocol as judged by the investigator
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 at screening.
- Patients with histologically or cytologically confirmed diagnosis of advanced stage:
- HER2 overexpression, defined as an immunohistochemistry score (IHC) of 2+ or 3+ in at least 10% of tumour cells without an activating HER2 mutation
Key exclusion criteria (6 listed)
- Contraindications for systemic treatment (as will be assigned by the treating physician)
- Pregnant or lactating women
- Prior allergic reaction to immunoglobulins or immunoglobulin allergy
- Inability to comply with study procedures
- Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the study results
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PET imaging with ⁸⁹Zr-trastuzumabParticipants will receive one injection of ⁸⁹Zr-trastuzumab and undergo a PET/CT scan four days later. | Diagnostic test | HER2-mutated NSCLC cohort and HER2-overexpressing NSCLC cohort |
| Blood sampling for pharmacokineticsTo assess the pharmacokinetics of ⁸⁹Zr-trastuzumab, the investigators collect blood samples at multiple time points following tracer administration. Samples are drawn at 10 minutes, 30 minutes, 1 hour, and 2 hours post-injection, and again on day 4 and day 7 post-injection. | Diagnostic test | HER2-mutated NSCLC cohort and HER2-overexpressing NSCLC cohort |
Primary outcome
Standard uptake values (SUVs) in tumor lesions
Time frame: During PET imaging with ⁸⁹Zr-trastuzumab
measurable tumor lesions and enlarged lymph nodes (>20 mm)
4 secondary outcomes
Tumor-to-background ratio (TBR)
Time frame: During PET imaging with ⁸⁹Zr-trastuzumab
Tumor-to-plasma ratio (TPR)
Time frame: During PET imaging with ⁸⁹Zr-trastuzumab
SUVs in tumor lesions
Time frame: During PET imaging with ⁸⁹Zr-trastuzumab
Total expression volume (TEV)
Time frame: During PET imaging with ⁸⁹Zr-trastuzumab
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer (NSCLC)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PET imaging with ⁸⁹Zr-trastuzumab and Blood sampling for pharmacokinetics in people with Lung Cancer (NSCLC) and HER2 Expression, run by The Netherlands Cancer Institute at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 28 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joop de Langen (+31205129111, j.d.langen@nki.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Standard uptake values (SUVs) in tumor lesions (time frame: During PET imaging with ⁸⁹Zr-trastuzumab). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.